Transplant Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Transplant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 169 trials

Recruiting
Phase 1Phase 2

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation
National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418
Recruiting
Phase 2

Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaTransplantation, Stem Cell+1 more
The First Affiliated Hospital of Soochow University48 enrolled1 locationNCT06816134
Recruiting

Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

CancerMetabolic DiseaseChronic Kidney Diseases+3 more
University Hospital, Toulouse5,000 enrolled1 locationNCT05318196
Recruiting
Not Applicable

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

Heart FailureHeart TransplantTransplant; Failure, Heart
XVIVO Perfusion60 enrolled14 locationsNCT06895070
Recruiting

Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease

Pediatric ALLCongenital Heart DiseaseHeart Transplantation
University of Alberta20 enrolled1 locationNCT06325280
Recruiting
Not Applicable

HIIT in Pediatric Heart Transplant Recipients (MedBIKE™)

Pediatric ALLTransplant; Failure, Heart
University of Alberta10 enrolled1 locationNCT05451979
Recruiting
Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

End Stage Renal DiseaseDelayed Graft FunctionDeceased Donor Kidney Transplant
Apellis Pharmaceuticals, Inc.320 enrolled1 locationNCT07020832
Recruiting
Phase 2

Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant

Allogeneic Stell Cell TransplantViral Infection
Children's Hospital Medical Center, Cincinnati180 enrolled1 locationNCT04230356
Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled3 locationsNCT06707493
Recruiting
Phase 2

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

COVID-19Inflammatory Bowel DiseaseRheumatoid Arthritis (RA)+5 more
McGill University Health Centre/Research Institute of the McGill University Health Centre660 enrolled3 locationsNCT06599658
Recruiting
Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Hematologic MalignancyRelapsed Pediatric ALLHematopoietic Cell Transplantation
St. Jude Children's Research Hospital60 enrolled1 locationNCT07257419
Recruiting
Phase 2

Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

Liver TransplantHepatocellular Carcinoma RecurrentSystemic Treatment
Assistance Publique - Hôpitaux de Paris50 enrolled10 locationsNCT06254248
Recruiting
Phase 2

Orphan Indications for CD19 Redirected Autologous T Cells

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD133 enrolled1 locationNCT04276870
Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

Metabolic DiseaseDiabetes Mellitus, Type 1Type 1 Diabetes+14 more
Otsuka Pharmaceutical Factory, Inc.13 enrolled1 locationNCT06575426
Recruiting
Phase 3

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

B-ALLMRD-positiveAllogenetic Hematopoietic Stem Cell Transplantation
Peking University People's Hospital70 enrolled1 locationNCT07441291
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Multiple MyelomaPost-transplant MRD-guided Maintenance TherapyPre-transplant Purging
M.D. Anderson Cancer Center40 enrolled1 locationNCT06207799
Recruiting
Not Applicable

Fecal Microbiota Transplantation Intervention on Microbiota Composition and Insulin Sensitivity in Diabetes

Diabetes Mellitus, Type 2Continuous Glucose MonitoringFecal Microbiota Transplantation (FMT)+1 more
Central Jutland Regional Hospital16 enrolled1 locationNCT07375797
Recruiting
Phase 2

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

Kidney Transplantation
Singulera Therapeutics Inc.34 enrolled7 locationsNCT06552169